Overview of the Sage Therapeutics Lawsuit
Levi & Korsinsky, LLP has alerted investors regarding a class action lawsuit involving Sage Therapeutics, Inc. The legal action is focused on claims of securities fraud that have reportedly affected shareholders from April 12, 2021, through July 23, 2024.
Details of the Class Action
This lawsuit aims to recover losses for investors who may have been misled by the company's statements. Allegations include misleading information about the effectiveness of Zuranolone, a neuroactive steroid intended for postpartum depression treatment. The lawsuit argues that the drug's efficacy for Major Depressive Disorder (MDD) was overstated, and there were doubts about the FDA's approval for MDD based on the current data.
Additional Allegations against Sage Therapeutics
The complaint further claims that clinical results for SAGE-718, designed for Mild Cognitive Impairment due to Parkinson’s Disease, and SAGE-324, aimed at treating essential tremor, were not only overcomplicated but also misrepresented to investors.
Key Deadlines and Actions for Investors
Investors who suffered financial losses during this timeframe have until October 28, 2024, to take action. Being appointed as a lead plaintiff could help highlight the grievances experienced by shareholders.
No Fees Involved for Participants
If you are part of the potential class members involved in this lawsuit, engaging in this process comes with no financial obligation. You can pursue compensation without upfront costs.
Why Choose Levi & Korsinsky?
Levi & Korsinsky brings two decades of experience, securing substantial settlements for shareholders. Their dedicated team comprises over 70 professionals specializing in complex securities litigations, maintaining a prominent position as one of the leading firms in this area.
Contact Levi & Korsinsky for More Information
If you're considering participating or simply want more information about the lawsuit, reach out to Joseph E. Levi, Esq. at (212) 363-7500 or via email. The firm is located at 33 Whitehall Street, 17th Floor, New York, NY 10004.
Frequently Asked Questions
What is the lawsuit against Sage Therapeutics about?
The lawsuit alleges securities fraud, claiming that Sage Therapeutics misrepresented the effectiveness of several of its treatments.
Who can participate in the class action?
Investors who experienced losses in Sage Therapeutics shares from April 12, 2021, to July 23, 2024, are eligible to participate.
What is the deadline for becoming a lead plaintiff?
The deadline to request to be appointed as a lead plaintiff is October 28, 2024.
Are there any costs associated with this lawsuit?
No, there are no costs or obligations for class members to participate.
How can I get more information about the lawsuit?
Investors can contact Levi & Korsinsky, LLP, for additional details and steps regarding the lawsuit.
